ReviewFrontiers in immunology2025
The multifaceted roles and diagnostic-therapeutic potential of LINC01410 in malignant tumors and non-malignant disorders.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bufalin targets E2F2 to transcriptionally inhibit LINC01410 and suppress Wnt/β-catenin signaling in esophageal squamous cell carcinoma.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LINC01410 is a recently identified long non-coding RNA located on chromosome 9 that plays a multifaceted role in human diseases. Its dysregulation is closely associated with tumor initiation, progression, and therapeutic response. LINC01410 promotes oncogenesis by modulating key signaling pathways, such as PTEN/AKT, Notch, ErbB, and NF-κB, interacting with non-coding RNA networks, and influencing the expression of proteins involved in tumor biology. Beyond these roles, it contributes to cancer metabolism by regulating glycolysis, lipid droplet accumulation, and exosome-mediated intercellular communication, thereby shaping the tumor microenvironment and enhancing malignancy. Intriguingly, LINC01410 exhibits opposite expression patterns in non-malignant conditions such as preeclampsia and diabetic nephropathy, highlighting its context-dependent biological function. Collectively, these findings position LINC01410 as a pivotal regulator linking protein expression, metabolism, and intercellular signaling, underscoring its potential as a biomarker and therapeutic target in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.